# Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

> **NCT01223365** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 330 (actual)

## Conditions studied

- Chronic Pain

## Interventions

- **DRUG:** Hydrocodone ER

## Key facts

- **NCT ID:** NCT01223365
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2017-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01223365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01223365, "Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01223365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*